Ekaterina G. Kochkina

Ekaterina G. Kochkina

Auto-generated profile, based on publicly available information

Ekaterina G. Kochkina

I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry, Russian Academy of Sciences, 44 Thorez av, St. Petersburg, Russia, 194223

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2004 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
NNNatalia N. Nalivaeva
Natalia N. Nalivaeva
LFLilia Fisk
Lilia Fisk
EKEkaterina G. Kochkina
Ekaterina G. Kochkina
SPSvetlana A. Plesneva
Svetlana A. Plesneva
IZIgor A. Zhuravin
Igor A. Zhuravin
ATAnthony J. Turner
Anthony J. Turner

20 March 2015 in Biogerontology
Verified
Journal Article
Closed access
PDF file
EKEkaterina G. Kochkina
Ekaterina G. Kochkina
SPSvetlana A. Plesneva
Svetlana A. Plesneva
DVDmitrii Vasilev
Dmitrii Vasilev
IZIgor A. Zhuravin
Igor A. Zhuravin
ATAnthony J. Turner
Anthony J. Turner
NNNatalia N. Nalivaeva
Natalia N. Nalivaeva

1 January 2015 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
IZI. А. Zhuravin
I. А. Zhuravin
NNN. N. Nalivaeva
N. N. Nalivaeva
Daria Igorevna KozlovaDaria Igorevna Kozlova
Daria Igorevna Kozlova
EKE. G. Kochkina
E. G. Kochkina
YFYana Borisovna Fedorova
Yana Borisovna Fedorova
SGS. I. Gavrilova
S. I. Gavrilova
The activity of AChE, BChE and NEP was reduced in the blood serum of patients with a-MCI and, to the greater extent, in patients with AD compared to CG and correlated with the level of cognitive dysfunction evaluated by MMSE, ADAS-cog, and other tests. For the first time, it has been shown that treatment of a-MCI patients with ceraxon (citicolin) results in an increase of the activity of blood serum AChE, BChE and NEP to the values observed in the CG. Thus, the activities of blood serum AChE, BChE and NEP reflect the level of cognitive dysfunction and can be used as prognostic biomarkers of the level of dementia progression in patients with impaired memory.

20 April 2019 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
IZI. A. Zhuravin
I. A. Zhuravin
NDNadezhda M. Dubrovskaya
Nadezhda M. Dubrovskaya
DVDmitrii Vasilev
Dmitrii Vasilev
DKD. I. Kozlova
D. I. Kozlova
EKE. G. Kochkina
E. G. Kochkina
NNN. N. Nalivaeva
N. N. Nalivaeva

9 September 2011 in Neurochemical Journal
Verified
Journal Article
Closed access
PDF file
NNNatalia N. Nalivaeva
Natalia N. Nalivaeva
NMN. Z. Makova
N. Z. Makova
EKE. G. Kochkina
E. G. Kochkina
DJD. John
D. John
VAV. A. Arutyunov
V. A. Arutyunov
IZI. A. Zhuravin
I. A. Zhuravin
Age related decline of cognitive functions in humans is a result of degeneration of cholinergic neurones and acetylcholine deficit in certain brain structures. In this connection, inhibitors of cholinesterases capable of preventing further decline of acetylcholine levels are widely used for treatment of cognitive disorders, in particular in Alzheimer’s disease (AD). Despite a wide range of anticholinesterase drugs available to date most of them have side-effects and are not always beneficial in older patients. Moreover, there are two forms of cholinesterases, namely acetyl- and butyrylcholinesterases (AChE and BuChE) which have different levels of their expression, localisation and functions in the brain. Since with age there is a decrease of AChE activity and an increase of BuChE, the design of selective inhibitors for each enzyme is required. In the present work the effects of synthetic geroprotective peptides vilon (Lys-Glu) and epithalon (Ala-Glu-Asp-Gly) on the activity of AChE and BuChE in human neuroblasoma cells SH-SY5Y have been studied. Also we performed an analysis of the effects of these peptides on the activity of the α-secretase of amyloid precursor protein (APP) which participates in non-amyloidogenic processing of APP releasing a soluble fragment of APP, and possibly in formation of a soluble form of AChE. It was found that incubation of cells during 24 hours in the presence of 50 nM of vilon and epithalon resulted in a decrease of the activity of soluble and membrane-bound forms of AChE and BuChE on average by 30–60%. Both peptides mostly inhibited membrane-bound forms of the enzymes but to a greater extent BuChE. Epithalon was also found to be capable of activation of α-secretase by 20–25%. The data obtained suggest that vilon and epithalon have selective anticholinesterase properties and that epithalon can also stimulate APP cleavage and increase production of its soluble neuroprotective form.